Veterans test daily cream to stop face skin cancers
NCT ID NCT05212246
First seen Jan 23, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This Phase 3 trial tests whether a daily imiquimod cream applied to the face for 12 weeks can prevent new basal cell carcinomas (BCC) in 1,630 veterans at high risk. Participants apply either the active cream or a placebo and are followed for up to 3 years with skin exams. The goal is to see if the cream reduces new BCCs on the face compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Providence VA Medical Center, Providence, RI
Providence, Rhode Island, 02908-4734, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imiquimod cream (5%)
What this could lead to
If it works, this could offer a way to prevent new basal cell skin cancers on the face in people at high risk.
What could go wrong
This is a large Phase 3 trial, but it only includes veterans and focuses on the face. Side effects like skin irritation may limit use, and results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.